Photo by diabetesmagazijn from unsplash
What is the central question of this study? Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular risk in patients with both diabetic and non‐diabetic kidney disease: can SGLT2 inhibition improve renal… Click to show full abstract
What is the central question of this study? Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular risk in patients with both diabetic and non‐diabetic kidney disease: can SGLT2 inhibition improve renal pressure natriuresis (PN), an important mechanism for long‐term blood pressure control, which is impaired in type 1 diabetes mellitus (T1DM)? What is the main finding and its importance? The SGLT2 inhibitor dapagliflozin did not enhance the acute in vivo PN response in either healthy or T1DM Sprague–Dawley rats. The data suggest that the mechanism underpinning the clinical benefits of SGLT2 inhibitors on health is unlikely to be due to an enhanced natriuretic response to increased blood pressure.
Journal Title: Experimental Physiology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!